P·01 Products / Immune checkpoint
Clone TG1 · Cat. no. DIA-TG1-M · RRID AB_3750391
TIGIT is expressed on T cells in tumors. The ultra-validated clone TG1 allows the identification of TIGIT-positive T cells in human tumor tissue sections (FFPE). The new clone TG2 shows a stronger staining intensity.
12 clone-specific peer-reviewed publications
Clone TG1 has been validated on large quantities of tumor tissues and beta-tested by different labs for IHC-FFPE. With antibody clone TG1, TIGIT could for the first time be detected immunohistochemically in tumor tissue.
Full list with DOI and PMID: publications.
Mouse monoclonal antibody for studying TIGIT in human FFPE tissue. Clone TG1 is documented by twelve peer-reviewed references, covering brightfield IHC, automated platforms and fluorescence multiplex IHC.
TG1 is documented by twelve peer-reviewed references — including Hodgkin lymphoma, seminoma, lung cancer, gallbladder cancer, colorectal cancer, melanoma, uveal melanoma, cutaneous squamous cell carcinoma and Merkel cell carcinoma. Three AACR congress presentations on TIGIT are documented in section P·12.
A systematic study evaluated 1,778 tumors representing 86 tumor entities and also documented TG1 in normal and inflammatory tissues, with Western blotting, ELISA and pre-absorption reported as specificity assessments.
Documented manual and Leica Bond RX starting protocols; independent studies report Dako Autostainer Link 48, Agilent Omnis and fluorescence multiplex IHC. Conditions must be validated in the user's laboratory.
IHC image gallery and ONCOdianova reference images: section P·03 ↓
P·02 TIGIT antibody clones
A growing number of immune checkpoints are emerging as targets for anticancer therapy. Cancer immunology studies have shown that cancer cells, together with cells of the surrounding microenvironment, generate co-inhibitory signals by upregulating the expression of components that suppress the antitumor immune response. The TIGIT pathway interacts with different inhibitory checkpoint pathways. TIGIT provides significant promise for immunotherapy, especially in combination with other immune checkpoint inhibitors.
The immunoreceptor TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a member of the poliovirus receptor (PVR) family. Expression of TIGIT has been reported on NK cells, regulatory T cells, follicular T helper cells, memory CD4+ T cells, and CD8+ T cells, but TIGIT is not expressed on B cells or naive CD4+ T cells. TIGIT acts as an inhibitory immune checkpoint on both T cells and natural killer (NK) cells by a highly complex pathway. Known ligands for TIGIT include CD155 and CD112. Moreover, the TIGIT/CD155/CD112 network also interacts with further checkpoint regulators.
In inflammation and in multiple cancer models, T cells have been shown to upregulate TIGIT expression. In several types of cancer, the ligands CD155 and CD112 are also highly expressed on dendritic cells and macrophages. Moreover, TIGIT expression is highly correlated with the expression of other co-inhibitory molecules, including PD-1. In addition to directly inhibiting cytotoxic T-cell activity, TIGIT can stimulate an immunosuppressive microenvironment by influencing other immune cells: for example, TIGIT binds CD155 on the surface of dendritic cells or manipulates NK cell activity. Drugs inhibiting TIGIT activity are currently being developed.
The newly developed clone TG2 has a higher affinity to the target protein TIGIT and shows a stronger staining intensity in IHC studies on tonsil when compared to TG1.
TG1 and TG2 are separate clones with their own product data and catalog numbers. Product data and publications for TG2 are on the TG2 page. NCBI-verified TIGIT cell biology with clone TG1 in human FFPE tissue is documented below in the TIGIT in research section.
Product information
P·03 IHC gallery
IHC figures and legends on TIGIT detection in multiple tumors.
7 figures (10 images) from Tech Note V1 and datasheet V17 (clone TG1): tonsil at three magnifications, retrieval comparison on the Leica Bond RX, Western blot, tonsil (datasheet), Hashimoto thyroiditis, colorectal carcinoma and sarcoid granuloma.
Microphotographs of TG-1 immunostaining on human tonsil at 100×, 200× and 400× (ONCOdianova reference images, Tech Note V1, Fig. 1).
Antibody dilution 1:50 · antigen retrieval: autoclave in TEC buffer (Tris-EDTA-citrate, pH 7.8) at 121 °C for 5 min · Zeiss Axiocam MRc camera, AxioVision SE64 software, Zeiss Axioskop 40 microscope · no image enhancement or manipulation.
Normal human tonsil with numerous TIGIT-positive lymphocytes (ONCOdianova reference image, datasheet V17, Fig. A).
Datasheet figure heading: „Immunohistochemistry of human TG1 in routine formalin-fixed paraffin-embedded tissue samples“. Different field of view from the Tech Note tonsil series.
TIGIT IHC on tonsil after heat-induced epitope retrieval at pH 9.0 (left) versus pH 6.0 (right), Leica Bond RX (ONCOdianova reference images, Tech Note V1, p. 5).
The signal at pH 9.0 is markedly stronger than at pH 6.0 – a retrieval comparison at two pH values.
Western blot using recombinant TIGIT protein as a target for TG-1 (ONCOdianova reference image, Tech Note V1, Fig. 2). Increasing amounts of recombinant TIGIT (ng); antibody 1:500 in 5 % milk/PBST; band at approx. 20 kDa.
Documents antibody binding to the recombinant protein under the stated conditions.
Inflammatory lymphoid infiltrate in Hashimoto thyroiditis (ONCOdianova reference image, datasheet V17, Fig. C).
Same photograph and legend as datasheet V17, figure C („Immunohistochemistry of human TG1 in routine FFPE tissue samples“); the datasheet shows a crop of this original (1772 × 1181 px).
Tumor infiltrating lymphocytes in colorectal carcinoma (ONCOdianova reference image, datasheet V17, Fig. B).
Membranous lymphocyte staining is scored as the TIGIT signal.
Sarcoid granuloma interspersed with TIGIT-positive lymphocytes (ONCOdianova reference image, datasheet V17, Fig. D).
41 cases from the ONCOdianova TIGIT tissue gallery. They document TIGIT-positive lymphocytes in normal lymphatic tissue, mucosa and tumors of various organs.
Strong TIGIT expression in a large number of tumor infiltrating lymphocytes in a seminoma with dense lymphocytic infiltrate.
Strong TIGIT expression in tumor infiltrating lymphocytes in a seminoma with sparse lymphocytic infiltrate.
High fraction of TIGIT positive cells in peritumoral lymphocytes in a case of penis carcinoma.
Low grade neuroendocrine carcinoma with scattered infiltrate containing TIGIT positive lymphocytes.
High grade neuroendocrine carcinoma with focal accumulation of TIGIT positive lymphocytes.
Dense peritumoral and intratumoral infiltrate of TIGIT positive lymphocytes in a case of a poorly differentiated squamous cell carcinoma of the esophagus.
High frequency of TIGIT positive lymphocytes in a lymphoepithelial carcinoma.
Dense peritumoral infiltrate of TIGIT positive lymphocytes in a laryngeal squamous cell carcinoma.
Invasive urothelial carcinoma with dense peritumoral and intratumoral infiltrate of TIGIT positive lymphocytes.
TIGIT IHC, overview and detail.
High frequency of TIGIT positive lymphocytes in a Hodgkin lymphoma.
TIGIT positive lymphocytes are present in the peritumoral and intratumoral lymphocytic infiltrate of a squamous cell carcinoma of the lung.
High frequency of TIGIT positive intratumoral lymphocytes in a squamous cell carcinoma of the lung.
TIGIT positive lymphocytes are located peritumoral but not intratumoral in a squamous cell carcinoma.
Sparse TIGIT positive lymphocytes in a squamous cell carcinoma of the lung with strong desmoplastic reaction.
High density of TIGIT positive lymphocytes in a squamous cell carcinoma of the lung.
TIGIT positive lymphocytes in a bronchioloalveolar carcinoma of the lung.
High frequency of TIGIT positive lymphocytes in an adenocarcinoma of the lung.
High frequency of peritumoral TIGIT positive lymphocytes in a large cell adenocarcinoma of the lung.
Abundant TIGIT positive lymphocytes in an adenocarcinoma of the ampulla of Vater.
High number of TIGIT positive lymphocytes in an angiosarcoma.
Frequent TIGIT positive lymphocytes in a liposarcoma.
TIGIT positive lymphocytes are abundant in a Warthin tumor.
Dense infiltration of an ovarian carcinoma by TIGIT positive lymphocytes.
A cervix uteri squamous cell carcinoma with numerous intratumoral TIGIT positive lymphocytes.
Squamous cell carcinoma of the uterine cervix with peritumoral and intratumoral infiltrate of TIGIT positive lymphocytes.
Squamous cell carcinoma of the uterine cervix with abundant intratumoral infiltrate of TIGIT positive lymphocytes.
Squamous cell carcinoma of the uterine cervix with a high number of intratumoral TIGIT positive lymphocytes.
Peritumoral TIGIT positive lymphocytes in a case of endometrium carcinoma.
High density of TIGIT positive lymphocytes in a medullary breast cancer.
A case of medullary breast cancer with abundant TIGIT positive lymphocytes.
High density of peritumoral and intratumoral TIGIT positive lymphocytes in a medullary breast cancer.
TIGIT positive lymphocytes in the subepithelial tissue of the lip (oral epithelium).
Oral mucosa with TIGIT positive lymphocytes in the subepithelial stroma.
Oral mucosa with intraepithelial and subepithelial TIGIT positive lymphocytes.
Abundant TIGIT positive lymphocytes in the spleen.
TIGIT positive lymphocytes are frequent in the thymus.
Thymus with high number of TIGIT positive lymphocytes.
TIGIT positive lymphocytes are abundant in the mucosa of the appendix.
Appendix mucosa with dense accumulation of TIGIT positive lymphocytes.
Appendix mucosa with TIGIT positive lymphocytes.
Overview left, detail right.
All images and legends are original ONCOdianova material. The reference images are the figures of Tech Note V1 and datasheet V17; they document staining with clone TG1 under the stated conditions. The TIGIT tissue gallery illustrates the tissues studied with ONCOdianova's anti-TIGIT immunohistochemistry.
P·04 Datasheet · Tech note · MSDS
Product data, instructions for use, references and figures A–D.
Download PDF ↓Manual and Leica Bond RX staining procedures, tonsil (100×/200×/400×), retrieval comparison and Western blot figures.
Download PDF ↓Material safety data sheet.
Download PDF ↓P·05 Description
| Product | Anti-TIGIT (Human) from Mouse |
|---|---|
| Catalog number | DIA-TG1-M (earlier presentation of the same clone: DIA-TG1, 200 µg) |
| Distributor catalog number | ODN-DIA-TG1-M (BIOZOL) |
| SKU | TIGIT |
| Product category | Cancer Immunology IHC marker |
| Specificity | TIGIT |
| Target | TIGIT — T-cell immunoreceptor with Ig and ITIM domains (Gene ID 201633, UniProt Q495A1) |
| Species reactivity | Human |
| Host species | Mouse |
| Isotype | Mouse IgG1/κ |
| Clone | TG1 (monoclonal) |
| RRID | AB_3750391 |
| Immunogen | Recombinant peptide from the extracellular domain of human TIGIT |
| Applications | IHC on FFPE tissue; Western blot |
| Conjugation | Unconjugated |
| IHC starting range | 1:50 – 1:150 — 1:50 for biotin/(strept)avidin-based detection, 1:100–1:150 for polymer-based detection; optimal dilution to be determined by the user for tissue, fixation, platform and detection system |
| Format | Lyophilized; antibody purified from culture supernatant |
| Quantity | 100 µl |
| Reconstitution | Restore to 100 µl with sterile distilled water; gentle shaking for 10 minutes |
| Buffer / formulation | PBS, pH 7.4, 2% BSA, 0.05% sodium azide |
| BSA-free variant | BSA-free high-concentration variant available on request |
| Epitope retrieval | Heat-induced epitope retrieval required; autoclave 121 °C, 5 min, Tris-EDTA-citrate pH 7.8 recommended |
| Positive control | Tonsil |
| Staining pattern | Membranous (lymphocyte subsets) |
| Storage | Lyophilized at 2–8 °C; long-term at −20 °C (stable for at least one year); reconstituted at 2–8 °C short term (several weeks); avoid repeated freeze/thaw cycles |
| Associated antibodies | DIA-TG2-M (anti-TIGIT, clone TG2) · DIA-R12 (anti-PVRIG/CD112R, clone R12) — as listed in the datasheet |
| Notice of use | For Research Use Only. Not for use in diagnostic procedures. |
| Manufacturer | ONCOdianova GmbH |
The technical data above are taken from datasheet V17 (25 Feb 2025) and tech note V1 (Nov 2019). RRID, gene and protein entries link to their registries; published staining conditions are documented in the publications section. The data apply to the current DIA-TG1-M product (100 µl). Published dilutions range from 1:25 to 1:150 depending on study and method; each laboratory must validate its own conditions.
P·06 Reactivity
Clone TG1 is the first monoclonal antibody detecting TIGIT in routine formalin-fixed paraffin-embedded (FFPE) tissues. TG1 has been validated for the detection of TIGIT-positive T cells with a focus on tumor infiltrating T cells (TILs). Anti-TIGIT clone TG1 allows the identification of TIGIT in the tumor microenvironment under pathological conditions.
TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a member of the poliovirus receptor (PVR) family. TIGIT is expressed on subsets of T lymphocytes and controls an immune checkpoint. The expression of TIGIT has been reported on NK cells, regulatory T cells, follicular T helper cells, memory CD4+ T cells, and CD8+ T cells, but TIGIT is not expressed on B cells or naive CD4+ T cells. Naive CD4+ T cells may upregulate TIGIT expression upon activation. In many different cancer models, TIGIT has been shown to be upregulated on T cells. The ligands CD155 and CD112 are also highly expressed on dendritic cells and macrophages in different cancer diseases. Moreover, TIGIT expression is highly correlated with the expression of further co-inhibitory molecules like PD-1. In addition to its direct inhibitory effect on cytotoxic T cells, TIGIT can stimulate an immunosuppressive microenvironment by influencing other immune cells: for example, TIGIT can bind CD155 on the surface of dendritic cells or is able to manipulate NK cell activity. TIGIT inhibiting drugs are currently being developed. Immunohistochemical (IHC) application of monoclonal antibody TG1 may provide valuable information for clinical research and potential therapeutic interventions specifically targeting TIGIT at its cancer immunology checkpoint.
Clone TG1 is the first monoclonal antibody for the immunohistochemical (IHC) detection of TIGIT (T-cell immunoreceptor with Ig and ITIM domains) in routine FFPE human tissue specimens. Furthermore, TG1 has been validated for the identification of TIGIT-positive T cells infiltrating human tumors, with the aim of allowing detection of TIGIT in the tumor microenvironment by IHC. Immunohistochemical (IHC) application of monoclonal antibody TG1 may provide valuable information for clinical research and potential therapeutic interventions specifically targeting the TIGIT-related tumor immunology checkpoint.
| Species reactivity | Human |
|---|---|
| Host species | Mouse |
| Detected with TG1 in FFPE tissue | CD8+ cytotoxic T cells, CD4+ T-helper cells, FOXP3+ regulatory T cells and NK cells |
| Positive control | Tonsil |
| Staining pattern | Membranous, lymphocyte subsets |
| Applications | IHC on human FFPE tissue; Western blot |
P·07 IHC protocols & published applications
ONCOdianova application protocol
Manual FFPE IHC — ONCOdianova protocol
Source: ONCOdianova Technical Note V01 “Anti-TIGIT / DIA-TG1 · clone TG1” — full document under Documents. The automated Leica Bond RX procedure of the same Technical Note is kept separate in procedure 2.
Peer-reviewed · with ONCOdianova involvement
Published brightfield IHC application — seminoma
Hinsch A. et al., Oncol Lett 2019;18(2):1497–1502 · doi:10.3892/ol.2019.10428
Peer-reviewed · with Dianova involvement
Published multiplex fluorescence IHC
Blessin N.C. et al., Dis Markers 2019:5160565 · doi:10.1155/2019/5160565 — the same study reports pH 7.8 and 1:70 for the brightfield procedure; the multiplex values do not apply to brightfield.
Independent third-party application
Published application — Leica BOND-III
Murakami D. et al., PLOS ONE 2022;17(3):e0265908 · doi:10.1371/journal.pone.0265908 — application reported by the research group, not an ONCOdianova protocol recommendation.
Independent third-party application
Published application — melanoma research
Niebel D. et al., Clin Epigenetics 2022;14:50 · doi:10.1186/s13148-022-01270-2 — application reported by the research group, not an ONCOdianova protocol recommendation.
The protocols and published workflows shown here represent documented application examples. Antibody dilution, antigen retrieval, detection chemistry and staining conditions may require laboratory-specific optimization and validation.
Documented starting protocols. Both procedures come from Tech Note V1 (November 2019) for clone TG1. The stock concentration of 0.4 mg/ml and the reconstitution in 500 µl stated there belong to the DIA-TG1 format (200 µg); DIA-TG1-M (100 µl) is reconstituted in 100 µl. Dilutions of 1:50 – 1:150 are starting values; each laboratory validates tissue, fixation, platform and detection itself.
* TBST wash buffer (#K8000, DAKO)
** Incubate 5 min after the autoclave has reached 121 °C
*** TEC stock solution = 20× Tris-EDTA-citrate buffer: per 1 l distilled water dissolve 5 g Trizma base (Sigma T 1503), 10 g EDTA (Merck 1.08418.0250), 6.4 g trisodium citrate (Sigma C 0909); adjust to pH 7.8 using 1 mol/l HCl
According to datasheet V17, an automated protocol was established on the Leica Bond RX. Independent publications additionally document use on the Dako Autostainer Link 48 and Agilent Omnis (see publications).
Dispense volume per step 150 µl according to the Tech Note. The Tech Note additionally shows a tonsil staining comparing HIER at pH 9.0 versus pH 6.0, with a markedly stronger signal at pH 9.0 – see the reference image “Bond RX, HIER pH 9.0 / pH 6.0” in the IHC gallery (P·03).
P·08 References
The twelve references document TIGIT immunohistochemistry on human tissue. Eleven of them used clone TG1 (DIA-TG1); Scimeca et al. 2019 is listed in ONCOdianova datasheet V17 under “References for clone TG1”. A biomarker named in a publication title is the subject of that study, not an ONCOdianova product. Reported platform and dilution details document the respective published use. AACR congress presentations are documented in thecongress presentations section.
P·09 Interpretation guide
Documented is membranous staining of various lymphocyte subtypes. Tonsil is the documented positive control; in the published TMA study, TIGIT was detected in CD8+, CD4+ and FOXP3+ T cells and NK cells, but not in B cells, macrophages or dendritic cells.[1]
Tonsil is the documented positive control for TG1; datasheet V17 and Tech Note V1 name it for the manual and for the automated procedure. Membranous lymphocyte staining is scored as TIGIT positivity; run positive and negative controls in parallel.
Western blotting, ELISA and pre-absorption are reported as specificity assessments,[1] and binding to recombinant TIGIT is documented.
P·10 Target background
TIGIT (T-cell immunoreceptor with Ig and ITIM domains; also VSTM3, VSIG9) is an inhibitory receptor of the poliovirus receptor/nectin family. Upon binding its ligands CD155 (PVR) and CD112 (nectin-2), which are expressed on antigen-presenting cells, it delivers inhibitory signals to T cells and NK cells (UniProt Q495A1).
In human FFPE tissue studied with clone TG1, TIGIT was detected in CD8+ cytotoxic T cells, CD4+ T-helper cells, FOXP3+ regulatory T cells and NK cells, but not in CD11c+ dendritic cells, CD68+ macrophages or CD20+ B lymphocytes. TIGIT expression paralleled that of PD-1: more than 70% of TIGIT+ cells were PD-1+, and more than 90% of PD-1+ cells were TIGIT+. In tonsil, expression increased from the interfollicular area towards the germinal centre; among inflammatory diseases, the strongest signal was found in Hashimoto thyroiditis.[1]
TIGIT+ lymphocytes were seen in all 86 tumour entities examined, with considerable variability within and between entities and particularly high densities in squamous cell cancers of various origins.[1]In Hodgkin lymphoma, 9–99% (median 86%) of lymphoid background cells were TIGIT+, with TIGIT and PD-1 localising to the same cells.[2] TIGIT is therefore studied as an inhibitory checkpoint receptor of the tumour microenvironment. Clone TG1 is a research tool for such studies.
Bracketed numbers refer to the publication list below. Target biology is kept separate from clone-specific product claims.
P·11 Translational research relevance
TIGIT is an inhibitory immune-checkpoint receptor and a therapeutically investigated target. Tissue TIGIT expression has been analyzed by brightfield and multiplex IHC and, in independent studies, in relation to the tumor immune contexture and to response under anti-PD-1 therapy.
Clone TG1 can be used to study TIGIT-positive lymphocytes in human FFPE tissue — by brightfield IHC, on automated platforms and in fluorescence multiplex IHC — and is documented by twelve peer-reviewed references, including a systematic study of 1,778 tumors across 86 entities.
TG1 is a research-use antibody for studying TIGIT-positive lymphocytes in human FFPE tissue. For Research Use Only. Not for use in diagnostic procedures.
P·12 AACR congress presentations
Three poster presentations on TIGIT from the American Association for Cancer Research (AACR) Annual Meeting, Chicago, are available as original PDFs for download.
“Prevalence of TIGIT expression in normal tissues, inflammation, and cancer.” Blessin NC et al., Institute of Pathology, University Medical Center Hamburg-Eppendorf; Dianova GmbH, Hamburg.
Download PDF ↓“High variability of TIGIT expression in Hodgkin’s lymphoma.” Simon R et al., Institute of Pathology, University Medical Center Hamburg-Eppendorf; Dianova GmbH, Hamburg.
Download PDF ↓“Expression and Significance of PVR-TIGIT/CD226, An Immune Checkpoint Axis in Small Cell Lung Cancer.” Yu H et al.; data provided by the Hirsch Biomarker Analysis Laboratory, Anschutz Medical Campus, University of Colorado Denver, Aurora, CO, USA.
Download PDF ↓The related announcements are available in the scientific archive.
P·13 FAQ
TG1 is a mouse monoclonal antibody against human TIGIT (catalog number DIA-TG1-M), used as a research reagent. Clone-specifically published applications include IHC on FFPE tissue, brightfield IHC and fluorescence multiplex IHC.
Yes. Multiple peer-reviewed publications explicitly name TG1 or DIA-TG1 and document its use on human FFPE material.
The documented IHC starting range is 1:50 to 1:150 (1:50 for biotin/streptavidin-based detection, 1:100 to 1:150 for polymer-based detection). Published conditions range from 1:25 to 1:150 depending on study and method. Each laboratory must validate the optimal condition for its own workflow.
Heat-induced epitope retrieval is required. Stringent heat pretreatment is recommended in an autoclave at 121 °C for 5 minutes in Tris-EDTA-citrate buffer, pH 7.8 (TEC buffer); the documented Leica Bond RX protocol uses high-pH retrieval (ER2, pH 9.0, 100 °C, 20 min).
Yes. A Leica Bond RX protocol is documented in Tech Note V1. Independent peer-reviewed studies additionally report use on the Dako Autostainer Link 48 and Agilent Omnis. Conditions from these sources are starting points and must be validated locally.
TG1 stains cell membranes of various lymphocyte subtypes; this membranous signal is scored as TIGIT positivity. Tonsil is the recommended positive control and should be run in parallel with a negative control.
Yes. TG1 has been used in peer-reviewed fluorescence multiplex IHC studies. Published conditions apply to the respective experimental setups and must be re-optimized when transferred to other systems.
TG1 and TG2 are two separate mouse monoclonal hybridoma clones against human TIGIT with separate catalog numbers (DIA-TG1-M and DIA-TG2-M). TG1 is the clone-specifically published clone: twelve peer-reviewed references are documented for it, and it carries RRID AB_3750391. TG2 is documented by its own datasheet, and shows higher affinity, stronger tonsil staining intensity and higher dilutability compared with TG1 (documented on the TG2 page).
Twelve peer-reviewed references are documented for clone TG1, covering lymphatic tissue, inflammation and cancer (Blessin 2019), Hodgkin lymphoma (Li 2018; Annibali 2021), seminoma (Hinsch 2019), gallbladder cancer (Albrecht 2021), non-small cell lung cancer (Mori 2023), cutaneous squamous cell carcinoma and keratoacanthoma (Lonsdorf 2024), Merkel cell carcinoma (Toberer 2025), colorectal cancer (Murakami 2022), melanoma (Niebel 2022), uveal melanoma (Koch 2025) and prostate cancer (Scimeca 2019). Eleven of them used clone TG1 (DIA-TG1); Scimeca et al. 2019 is listed in ONCOdianova datasheet V17 under “References for clone TG1”. The full list with DOI and PMID is in the publications section of this page.
Human tonsil. Tonsil is the documented positive control, and a published study additionally used tonsil germinal centers as positive control on an automated platform.
A membranous staining pattern of various lymphocyte subtypes. In the published TMA study, TIGIT was detected with TG1 in CD8+, CD4+ and FOXP3+ T cells and NK cells, but not in B cells, macrophages or dendritic cells.
Yes. The Research Resource Identifier is AB_3750391, assigned to product DIA-TG1-M, clone TG1.
P·14 Ordering
Ordering. ONCOdianova products are purchased through our distribution partner BIOZOL Diagnostica Vertrieb GmbH, Oehleckerring 11–13, 22419 Hamburg, Germany — order requests by e-mail: order@biozol.de (CC info@oncodianova.com). See also order information.
Datasheet V17 (25 Feb 2025) is the current datasheet for DIA-TG1-M (100 µl). The DIA-TG1 format (200 µg) named in the historical documents is the predecessor presentation of the same clone. Related: TG2 (separate anti-TIGIT clone) · R12 (CD112R/PVRIG) · KK3 (CD73/NT5E) · TC8 (CD8) · FX3 (FOXP3).